Table 2.

Main clinical studies of platinum-based therapy in BRCA-mutant pancreatic ductal adenocarcinoma.

Authors/year	Study design	No. of patients	Disease stage	Results in BRCA1/2-WT patients	Results in BRCA1/2-mutant patients	P	Reference
Golan et al., 2014	Retrospective analysis	43	III–IV	mOS 13 months	mOS 15 months	0.77	[26]
Reiss et al., 2018	Retrospective Case-control	70	III–IV	mOS 15.5 months	mOS 20.1 months	0.002	[79]
Golan et al., 2017	Retrospective case-control	74	I–II	mOS 43.8 months	mOS 44.4 months	0.775	[32]
Yu et al., 2019	Retrospective case-control	96	I–II	mOS 23.2 months	mOS 46.6 months	0.0156	[80]
Wattenberg et al., 2020	Retrospective case-control	78	III–IV	ORR 21%	ORR 58%	0.0022	[81]
O Reilly et al., 2020	Phase II, randomised	50	III–IV	–	RR 74.1% cisplatin–gemcitabine (arm A) versus 65.2% cisplatin–gemcitabine plus veliparib (arm B)	0.55	[82]

WT wild type, mOS median overall survival, m months, ORR objective response rate, RR response rate.